BRAINSTORM CELL THERAPEUTICS news, videos and press releases
For more news please use our advanced search feature.
BRAINSTORM CELL THERAPEUTICS - More news...
BRAINSTORM CELL THERAPEUTICS - More news...
- BrainStorm Issues 2024 Letter to Shareholders
- BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update
- BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
- BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024
- BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
- BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
- BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting
- BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit
- BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting
- BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update
- BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program
- BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
- BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
- BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
- BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
- BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
- BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
- BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
- BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
- BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
- BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
- BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
- BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
- BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
- BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
- SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
- BCLI FINAL DEADLINE TUESDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm - BCLI
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
